| Issue Date | Title | Author(s) |
| Mar-2021 | Clinical recommendations for perioperative immunotherapy-induced adverse events in patients with non-small cell lung cancer | Ni, Jun; Huang, Miao; Zhang, Li; Wu, Nan; Bai, Chun-Xue; Chen, Liang-An; Liang, Jun; Liu, Qian; Wang, Jie; Wu, Yi-Long; Zhang, Feng-Chun; Zhang, Shu-Yang; Chen, Chun; Chen, Jun; Fang, Wen-Tao; Gao, Shu-Geng; Hu, Jian; Jiang, Tao; Li, Shan-Qing; Li, He-Cheng; Liao, Yong-De; Liu, Yang; Liu, De-Ruo; Liu, Hong-Xu; Liu, Jian-Yang; Liu, Lun-Xu; Wang, Meng-Zhao; Wang, Chang-Li; Yang, Fan; Yang, Yue; Zhang, Lan-Jun; Zhi, Xiu-Yi; Zhong, Wen-Zhao; Guan, Yu-Zhou; Guo, Xiao-Xiao; He, Chun-Xia; Li, Shao-Lei; Li, Yue; Liang, Nai-Xin; Lu, Fang-Liang; Lv, Chao; Lv, Wei; Si, Xiao-Yan; Tan, Feng-Wei; Wang, Han-Ping; Wang, Jiang-Shan; Yan, Shi; Yang, Hua-Xia; Zhu, Hui-Juan; Zhuang, Jun-Ling; Zhuo, Ming-Lei |
| Jan-2020 | Disparity in clinical outcomes between pure and combined pulmonary large-cell neuroendocrine carcinoma: A multi-center retrospective study | Zhang, Jia-Tao; Li, Ye; Yan, Li-Xu; Zhu, Zheng-Fei; Dong, Xiao-Rong; Chu, Qian; Wu, Lin; Zhang, Hong-Mei; Xu, Chun-Wei; Lin, Gen; Yu, Zong-Yang; Hu, Jie; Zhu, Bo; Wang, Hui-Juan; Yang, Fan; Song, Zheng-Bo; Han, Zheng-Bo; Li, Meng-Xia; Lin, Jie; Wu, Yi-Long; Wang, Jin-Liang; Zhong, Wen-Zhao |
| 2019 | Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study | Zhong, Wen-Zhao; Chen, Ke-Neng; Chen, Chun; Gu, Chun-Dong; Wang, Jun; Yang, Xue-Ning; Mao, Wei-Min; Wang, Qun; Qiao, Gui-Bin; Cheng, Ying; Xu, Lin; Wang, Chang-Li; Chen, Ming-Wei; Kang, Xiaozheng; Yan, Wanpu; Yan, Hong-Hong; Liao, Ri-Qiang; Yang, Jin-Ji; Zhang, Xu-Chao; Zhou, Qing; Wu, Yi-Long |
| 2018 | Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study | Zhong, Wen-Zhao; Wang, Qun; Mao, Wei-Min; Xu, Song-Tao; Wu, Lin; Shen, Yi; Liu, Yong-Yu; Chen, Chun; Cheng, Ying; Xu, Lin; Wang, Jun; Fei, Ke; Li, Xiao-Fei; Li, Jian; Huang, Cheng; Liu, Zhi-Dong; Xu, Shun; Chen, Ke-Neng; Xu, Shi-Dong; Liu, Lun-Xu; Yu, Ping; Wang, Bu-Hai; Ma, Hai-Tao; Yan, Hong-Hong; Yang, Xue-Ning; Zhou, Qing; Wu, Yi-Long |
| 1-Mar-2021 | Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial | Zhong, Wen-Zhao; Wang, Qun; Mao, Wei-Min; Xu, Song-Tao; Wu, Lin; Wei, Yu-Cheng; Liu, Yong-Yu; Chen, Chun; Cheng, Ying; Yin, Rong; Yang, Fan; Ren, Sheng-Xiang; Li, Xiao-Fei; Li, Jian; Huang, Cheng; Liu, Zhi-Dong; Xu, Shun; Chen, Ke-Neng; Xu, Shi-Dong; Liu, Lun-Xu; Yu, Ping; Wang, Bu-Hai; Ma, Hai-Tao; Yang, Jin-Ji; Yan, Hong-Hong; Yang, Xue-Ning; Liu, Si-Yang; Zhou, Qing; Wu, Yi-Long |
| 8-Nov-2021 | Genomic signatures define three subtypes of EGFR-mutant stage II-III non-small-cell lung cancer with distinct adjuvant therapy outcomes | Liu, Si-Yang; Bao, Hua; Wang, Qun; Mao, Wei-Min; Chen, Yedan; Tong, Xiaoling; Xu, Song-Tao; Wu, Lin; Wei, Yu-Cheng; Liu, Yong-Yu; Chen, Chun; Cheng, Ying; Yin, Rong; Yang, Fan; Ren, Sheng-Xiang; Li, Xiao-Fei; Li, Jian; Huang, Cheng; Liu, Zhi-Dong; Xu, Shun; Chen, Ke-Neng; Xu, Shi-Dong; Liu, Lun-Xu; Yu, Ping; Wang, Bu-Hai; Ma, Hai-Tao; Yan, Hong-Hong; Dong, Song; Zhang, Xu-Chao; Su, Jian; Yang, Jin-Ji; Yang, Xue-Ning; Zhou, Qing; Wu, Xue; Shao, Yang; Zhong, Wen-Zhao; Wu, Yi-Long |
| 19-Sep-2022 | Induction immune-checkpoint inhibitors for resectable oncogene-mutant NSCLC: A multicenter pooled analysis | Zhang, Chao; Chen, Hua-Fei; Yan, Shi; Wu, Lin; Yan, Li-Xu; Yan, Xiao-Long; Yue, Dong-Sheng; Xu, Chun-Wei; Zheng, Min; Li, Ji-Sheng; Liu, Si-Yang; Yang, Ling-Ling; Jiang, Ben-Yuan; Ou, Qiu-Xiang; Qiu, Zhen-Bin; Shao, Yang; Wu, Yi-Long; Zhong, Wen-Zhao |
| Mar-2020 | Multiple Pulmonary Resections for Synchronous and Metachronous Lung Cancer at Two Chinese Centers | Kang, Xiaozheng; Zhang, Chao; Zhou, Haitao; Zhang, Jiatao; Yan, Wanpu; Zhong, Wen-Zhao; Chen, Ke-Neng |
| Dec-2020 | Quality of life with adjuvant gefitinib versus vinorelbine plus cisplatin in patients with completely resected stage II-IIIA (N1-N2) EGFR-mutant non-small-cell lung cancer: Results from the ADJUVANT (CTONG1104) study | Zeng, Jian; Mao, Wei-Min; Chen, Qi-Xun; Luo, Tao-Bo; Wu, Yi-Long; Zhou, Qing; Yang, Xue-Ning; Yan, Hong-Hong; Zhong, Wen-Zhao; Wang, Qun; Xu, Song-Tao; Wu, Lin; Shen, Yi; Liu, Yong-Yu; Chen, Chun; Cheng, Ying; Xu, Lin; Wang, Jun; Fei, Ke; Li, Xiao-Fei; Li, Jian; Huang, Cheng; Liu, Zhi-Dong; Xu, Shun; Chen, Ke-Neng; Xu, Shi-Dong; Liu, Lun-Xu; Yu, Ping; Wang, Bu-Hai; Ma, Hai-Tao |
| Dec-2024 | Redox<SUP>high</SUP> phenotype mediated by KEAP1/STK11/SMARCA4/NRF2 mutations diminishes tissue-resident memory CD8+T cells and attenuates the efficacy of immunotherapy in lung adenocarcinoma | Wei, Xue-Wu; Lu, Chang; Zhang, Yi-Chen; Fan, Xue; Xu, Chong-Rui; Chen, Zhi-Hong; Wang, Fen; Yang, Xiao-Rong; Deng, Jia-Yi; Yang, Ming-Yi; Gou, Qing; Mei, Shi-Qi; Luo, Wei-Chi; Zhong, Ri-Wei; Zhong, Wen-Zhao; Yang, Jin-Ji; Zhang, Xu-Chao; Tu, Hai-Yan; Wu, Yi-Long; Zhou, Qing |
| 2019 | The Unique Spatial-Temporal Treatment Failure Patterns of Adjuvant Gefitinib Therapy: A Post Hoc Analysis of the ADJUVANT Trial (CTONG 1104) | Xu, Song-Tao; Xi, Jun-Jie; Zhong, Wen-Zhao; Mao, Wei-Min; Wu, Lin; Shen, Yi; Liu, Yong-Yu; Chen, Chun; Cheng, Ying; Xu, Lin; Wang, Jun; Fei, Ke; Li, Xiao-Fei; Li, Jian; Huang, Cheng; Liu, Zhi-Dong; Xu, Shun; Chen, Ke-Neng; Xu, Shi-Dong; Liu, Lun-Xu; Yu, Ping; Wang, Bu-Hai; Ma, Hai-Tao; Yan, Hong-Hong; Yang, Xue-Ning; Zhang, Yong-Xing; Yin, Jia-Cheng; Wang, Qun; Wu, Yi-Long |
